Hydrocortisone

Last updated

Hydrocortisone
Cortisol3.svg
Cortisol-3D-balls.png
Clinical data
Trade names Cortef, others [1]
Other namesCortisol; 11β,17α,21-Trihydroxypregn-4-ene-3,20-dione; 11β,17α,21-Trihydroxyprogesterone
AHFS/Drugs.com Monograph
MedlinePlus a682206
License data
Pregnancy
category
Routes of
administration 		By mouth, intravenous, topical, rectal
Drug class Glucocorticoid; Mineralocorticoid
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Oral: 96 ± 20% [11] [12]
Protein binding 92 ± 2% (92–93%) [11] [12]
Metabolism 11β-HSDs Tooltip 11β-Hydroxysteroid dehydrogenases, others [12]
Metabolites Cortisone, others [12]
Onset of action Oral: 1.2 ± 0.4 hours (Tmax) [11]
Elimination half-life 1.2–2.0 hours [11] [12]
Duration of action 8–12 hours [13]
Identifiers
  • (8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C21H30O5
Molar mass 362.466 g·mol−1
3D model (JSmol)
  • O=C4\C=C2/[C@]([C@H]1[C@@H](O)C[C@@]3([C@@](O)(C(=O)CO)CC[C@H]3[C@@H]1CC2)C)(C)CC4
  • InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 Yes check.svgY
  • Key:JYGXADMDTFJGBT-VWUMJDOOSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Hydrocortisone is the name for the hormone cortisol when supplied as a medication. [14] It is a corticosteroid and works as an anti-inflammatory and by immune suppression. [1] Uses include conditions such as adrenocortical insufficiency, adrenogenital syndrome, high blood calcium, thyroiditis, rheumatoid arthritis, dermatitis, asthma, and COPD. [1] It is the treatment of choice for adrenocortical insufficiency. [15] It can be given by mouth, topically, or by injection. [1] Stopping treatment after long-term use should be done slowly. [1]

Contents

Side effects may include mood changes, increased risk of infection, and edema (swelling). [1] With long-term use, common side effects include osteoporosis, upset stomach, physical weakness, easy bruising, and candidiasis (yeast infections). [1] It is unclear if it is safe for use during pregnancy. [16]

Hydrocortisone was patented in 1936 and approved for medical use in 1941. [17] [18] It is on the World Health Organization's List of Essential Medicines. [19] It is available as a generic medication. [1] In 2022, it was the 202nd most commonly prescribed medication in the United States, with more than 2 million prescriptions. [20] [21]

Medical uses

Hydrocortisone is the pharmaceutical term for cortisol used in oral administration, intravenous injection, or topical application. It is used as an immunosuppressive drug, given by injection in the treatment of severe allergic reactions such as anaphylaxis and angioedema, in place of prednisolone in patients needing steroid treatment but unable to take oral medication, and perioperatively in patients on long-term steroid treatment to prevent an adrenal crisis. It may also be injected into inflamed joints resulting from diseases such as gout.[ citation needed ]

It may be used topically for allergic rashes, eczema, psoriasis, itching, and other inflammatory skin conditions. Topical hydrocortisone creams and ointments are available in most countries without prescription in strengths ranging from 0.05% to 2.5% (depending on local regulations) with stronger forms available by prescription only.[ citation needed ]

It may also be used rectally in suppositories to relieve the swelling, itch, and irritation in hemorrhoids. [7]

It may be used as an acetate form (hydrocortisone acetate), which has slightly different pharmacokinetics and pharmacodynamics. [7] [22]

Pharmacology

Pharmacodynamics

Hydrocortisone is a corticosteroid, acting specifically as both a glucocorticoid and as a mineralocorticoid. That is, it is an agonist of the glucocorticoid and mineralocorticoid receptors.[ citation needed ]

Hydrocortisone has low potency relative to synthetic corticosteroids. [13] Compared to hydrocortisone, prednisolone is about 4 times as potent and dexamethasone about 40 times as potent in terms of anti-inflammatory effect. [23] Prednisolone can also be used as cortisol replacement, and at replacement dose levels (rather than anti-inflammatory levels), prednisolone is about 8 times more potent than cortisol. [24] The equivalent doses and relative potencies of hydrocortisone compared to various other synthetic corticosteroids have also been reviewed and summarized. [13]

The endogenous production rate of cortisol is approximately 5.7 to 9.9 mg/m2 per day, which corresponds to an oral hydrocortisone dose of approximately 15 to 20 mg/day (for a 70-kg person). [25] [26] One review described daily cortisol production of 10 mg in healthy volunteers and reported that daily cortisol production could increase up to 400 mg in conditions of severe stress (e.g., surgery). [11]

The total and/or free concentrations of cortisol/hydrocortisone required for various glucocorticoid effects have been determined. [11]

Pharmacokinetics

Absorption

The bioavailability of oral hydrocortisone is about 96% ± 20% (SD). [11] [12] The pharmacokinetics of hydrocortisone are non-linear. [11] The peak level of oral hydrocortisone is 15.3 ± 2.9 (SD) μg/L per 1 mg dose. [11] The time to peak concentrations of oral hydrocortisone is 1.2 ± 0.4 (SD) hours. [11]

The topical percutaneous absorption of hydrocortisone varies widely depending on experimental circumstances and has been reported to range from 0.5 to 14.9% in different studies. [27] Some skin application sites, like the scrotum and vulva, absorb hydrocortisone much more efficiently than other application sites, like the forearm. [27] [28] [29] In one study, the amount of hydrocortisone absorbed ranged from 0.2% to 36.2% depending on the application site, with the ball of the foot having the lowest absorption and the scrotum having the highest absorption. [29] The absorption of hydrocortisone by the vulva has ranged from 4.4 to 8.1%, relative to 1.3 to 2.8% for the arm, in different studies and subjects. [29] [30] [31]

Distribution

Most cortisol in the blood (all but about 4%) is bound to proteins, including corticosteroid binding globulin (CBG) and serum albumin. A pharmacokinetic review stated that 92% ± 2% (SD) (92–93%) of hydrocortisone is plasma protein-bound. [11] Free cortisol passes easily through cellular membranes. [32] Inside cells it interacts with corticosteroid receptors. [33]

Metabolism

Hydrocortisone is metabolized by 11β-hydroxysteroid dehydrogenases (11β-HSDs) into cortisone, an inactive metabolite. [12] [11] It is additionally 5α-, 5β-, and 3α-reduced into dihydrocortisols, dihydrocortisones, tetrahydrocortisols, and tetrahydrocortisones. [34] [11] [12]

Elimination

The elimination half-life of hydrocortisone ranges from about 1.2 to 2.0 (SD) hours, with an average of around 1.5 hours, regardless of oral versus parenteral administration. [11] [12] The duration of action of systemic hydrocortisone has been listed as 8 to 12 hours. [13]

Chemistry

Hydrocortisone, also known as 11β,17α,21-trihydroxypregn-4-ene-3,20-dione, is a naturally occurring pregnane steroid. [35] [36] A variety of hydrocortisone esters exist and have been marketed for medical use. [35] [36]

Society and culture

In March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Efmody, intended for the treatment of congenital adrenal hyperplasia (CAH) in people aged twelve years and older. [37] The applicant for this medicinal product is Diurnal Europe BV. [37] Hydrocortisone (Efmody) was approved for medical use in the European Union, in May 2021, for the treatment of congenital adrenal hyperplasia (CAH) in people aged twelve years and older. [9]

Anti-competitive practices

In the UK, the Competition and Markets Authority (CMA) concluded an investigation into the supply of hydrocortisone tablets, finding that from October 2008 onwards, drug suppliers Auden McKenzie and Actavis plc had charged "excessive and unfair prices" for 10mg and 20mg tablets and entered into agreements with potential competitors, paying companies who agreed not to enter the hydrocortisone market and enabling Auden McKenzie and Actavis to supply the drugs as "generic" rather than branded products and thereby escape price controls until eventually other companies entered the market. Auden and Actavis overcharged the UK's National Health Service for over ten years. Fines totalling over £255m were levied against the companies involved in this breach of competition law. [38]

Research

COVID-19

Hydrocortisone was found to be effective in reducing mortality rate of critically ill COVID-19 patients when compared to other usual care or a placebo. [39]

Related Research Articles

<span class="mw-page-title-main">Corticosteroid</span> Class of steroid hormones

Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of vertebrates, as well as the synthetic analogues of these hormones. Two main classes of corticosteroids, glucocorticoids and mineralocorticoids, are involved in a wide range of physiological processes, including stress response, immune response, and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior.

<span class="mw-page-title-main">Cushing's syndrome</span> Symptoms from excessive exposure to glucocorticoids such as cortisol

Cushing's syndrome is a collection of signs and symptoms due to prolonged exposure to glucocorticoids such as cortisol. Signs and symptoms may include high blood pressure, abdominal obesity but with thin arms and legs, reddish stretch marks, a round red face due to facial plethora, a fat lump between the shoulders, weak muscles, weak bones, acne, and fragile skin that heals poorly. Women may have more hair and irregular menstruation or loss of menses, with the exact mechanisms of why still unknown. Occasionally there may be changes in mood, headaches, and a chronic feeling of tiredness.

<span class="mw-page-title-main">Cortisone</span> Corticosteroid precursor and metabolite of cortisol

Cortisone is a pregnene (21-carbon) steroid hormone. It is a naturally-occurring corticosteroid metabolite that is also used as a pharmaceutical prodrug. Cortisol is converted by the action of the enzyme corticosteroid 11-beta-dehydrogenase isozyme 2 into the inactive metabolite cortisone, particularly in the kidneys. This is done by oxidizing the alcohol group at carbon 11. Cortisone is converted back to the active steroid cortisol by stereospecific hydrogenation at carbon 11 by the enzyme 11β-Hydroxysteroid dehydrogenase type 1, particularly in the liver.

<span class="mw-page-title-main">Dexamethasone</span> Corticosteroid medication

Dexamethasone is a fluorinated glucocorticoid medication used to treat rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive pulmonary disease (COPD), croup, brain swelling, eye pain following eye surgery, superior vena cava syndrome, and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it may be used in combination with a mineralocorticoid medication such as fludrocortisone. In preterm labor, it may be used to improve outcomes in the baby. It may be given by mouth, as an injection into a muscle, as an injection into a vein, as a topical cream or ointment for the skin or as a topical ophthalmic solution to the eye. The effects of dexamethasone are frequently seen within a day and last for about three days.

<span class="mw-page-title-main">Prednisone</span> Steroid medication

Prednisone is a glucocorticoid medication mostly used to suppress the immune system and decrease inflammation in conditions such as asthma, COPD, and rheumatologic diseases. It is also used to treat high blood calcium due to cancer and adrenal insufficiency along with other steroids. It is taken by mouth.

<span class="mw-page-title-main">Glucocorticoid</span> Class of corticosteroids

Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones. Glucocorticoids are corticosteroids that bind to the glucocorticoid receptor that is present in almost every vertebrate animal cell. The name "glucocorticoid" is a portmanteau and is composed from its role in regulation of glucose metabolism, synthesis in the adrenal cortex, and its steroidal structure.

<span class="mw-page-title-main">Adrenal insufficiency</span> Insufficient production of steroid hormones by the adrenal glands

Adrenal insufficiency is a condition in which the adrenal glands do not produce adequate amounts of steroid hormones. The adrenal glands—also referred to as the adrenal cortex—normally secrete glucocorticoids, mineralocorticoids, and androgens. These hormones are important in regulating blood pressure, electrolytes, and metabolism as a whole. Deficiency of these hormones leads to symptoms ranging from abdominal pain, vomiting, muscle weakness and fatigue, low blood pressure, depression, mood and personality changes to organ failure and shock. Adrenal crisis may occur if a person having adrenal insufficiency experiences stresses, such as an accident, injury, surgery, or severe infection; this is a life-threatening medical condition resulting from severe deficiency of cortisol in the body. Death may quickly follow.

<span class="mw-page-title-main">Prednisolone</span> Corticosteroid medication

Prednisolone is a corticosteroid, a steroid hormone used to treat certain types of allergies, inflammatory conditions, autoimmune disorders, and cancers, electrolyte imbalances and skin conditions. Some of these conditions include adrenocortical insufficiency, high blood calcium, rheumatoid arthritis, dermatitis, eye inflammation, asthma, multiple sclerosis, and phimosis. It can be taken by mouth, injected into a vein, used topically as a skin cream, or as eye drops. It differs from the similarly named prednisone in having a hydroxyl at the 11th carbon instead of a ketone.

<span class="mw-page-title-main">Fludrocortisone</span> Mineralocorticoid hormone medication

Fludrocortisone, sold under the brand name Florinef, among others, is a corticosteroid used to treat adrenogenital syndrome, postural hypotension, and adrenal insufficiency. In adrenal insufficiency, it is generally taken together with hydrocortisone. Fludrocortisone is taken by mouth and is most commonly used in its acetate form.

<span class="mw-page-title-main">Triamcinolone</span> Steroid medication

Triamcinolone is a glucocorticoid used to treat certain skin diseases, allergies, and rheumatic disorders among others. It is also used to prevent worsening of asthma and chronic obstructive pulmonary disease (COPD). It can be taken in various ways including by mouth, injection into a muscle, and inhalation.

<span class="mw-page-title-main">Methylprednisolone</span> Corticosteroid medication

Methylprednisolone is a synthetic glucocorticoid, primarily prescribed for its anti-inflammatory and immunosuppressive effects. It is either used at low doses for chronic illnesses or used concomitantly at high doses during acute flares. Methylprednisolone and its derivatives can be administered orally or parenterally.

<span class="mw-page-title-main">Hydrocortisone acetate</span> Chemical compound

Hydrocortisone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.

<span class="mw-page-title-main">Mometasone</span> Steroid medication

Mometasone, also known as mometasone furoate, is a steroid medication used to treat certain skin conditions, hay fever, and asthma. Specifically it is used to prevent rather than treat asthma attacks. It can be applied to the skin, inhaled, or used in the nose. Mometasone furoate, not mometasone, is used in medical products.

<span class="mw-page-title-main">Deflazacort</span> Pharmaceutical drug

Deflazacort is a glucocorticoid belonging to acetonides or O-isopropylidene derivative. It is used as an anti-inflammatory and was patented in 1969 and approved for medical use in 1985. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication for Duchenne Muscular Dystrophy.

<span class="mw-page-title-main">11-Deoxycortisol</span> Chemical compound

11-Deoxycortisol, also known as cortodoxone (INN), cortexolone as well as 17α,21-dihydroxyprogesterone or 17α,21-dihydroxypregn-4-ene-3,20-dione, is an endogenous glucocorticoid steroid hormone, and a metabolic intermediate toward cortisol. It was first described by Tadeusz Reichstein in 1938 as Substance S, thus has also been referred to as Reichstein's Substance S or Compound S.

<span class="mw-page-title-main">Adrenal crisis</span> Medical emergency due to insufficient steroid production

Adrenal crisis, also known as Addisonian crisis or acute adrenal insufficiency, is a life-threatening complication of adrenal insufficiency. Hypotension, and hypovolemic shock, are the main symptoms of an adrenal crisis. Other symptoms include weakness, anorexia, nausea, vomiting, fever, fatigue, abnormal electrolytes, confusion, and coma. Laboratory testing may detect low sodium, high potassium, high lymphocyte count, high eosinophils, low blood sugar, and rarely high calcium. The biggest trigger for adrenal crisis is gastrointestinal illness. Those with primary adrenal insufficiency are at a higher risk for an adrenal crisis. The physiological mechanisms underlying an adrenal crisis involve the loss of endogenous glucocorticoids' typical inhibitory effect on inflammatory cytokines.

Critical illness–related corticosteroid insufficiency is a form of adrenal insufficiency in critically ill patients who have blood corticosteroid levels which are inadequate for the severe stress response they experience. Combined with decreased glucocorticoid receptor sensitivity and tissue response to corticosteroids, this adrenal insufficiency constitutes a negative prognostic factor for intensive care patients.

<span class="mw-page-title-main">Vamorolone</span> Chemical compound

Vamorolone, sold under the brand name Agamree, is a synthetic corticosteroid, which is used for the treatment of Duchenne muscular dystrophy. It is taken by mouth. It is a dual atypical glucocorticoid and antimineralocorticoid.

<span class="mw-page-title-main">Topical glucocorticoids</span>

Topical glucocorticoids are the topical forms of glucocorticoids. Topical glucocorticoids are used in the treatment of many skin conditions. They provide anti-inflammatory, antimitotic, and immune-system suppressing actions through various mechanisms.

<span class="mw-page-title-main">Topical hydrocortisone</span> Pharmaceutical drug

Topical hydrocortisone is a drug under the class of corticosteroids, which is used for the treatment of skin inflammation, itchiness and allergies. Some examples include insect bites, dermatitis and rash.

References

  1. 1 2 3 4 5 6 7 8 "Hydrocortisone". Drugs.com. American Society of Health-System Pharmacists. 9 February 2015. Archived from the original on 20 September 2016. Retrieved 30 August 2016.
  2. ↑ "Prescribing medicines in pregnancy database". Therapeutic Goods Administration (TGA). Archived from the original on 20 December 2016. Retrieved 21 February 2021.
  3. ↑ "Hydrocortisone Notice of enforcement policy" (PDF). FDA. Archived (PDF) from the original on 12 March 2023. Retrieved 31 December 2022.
  4. ↑ "Ala-cort- hydrocortisone cream". DailyMed. Archived from the original on 27 October 2020. Retrieved 21 February 2021.
  5. ↑ "Ala-scalp- hydrocortisone lotion". DailyMed. Archived from the original on 21 April 2021. Retrieved 21 February 2021.
  6. ↑ "Alkindi Sprinkle- hydrocortisone granule". DailyMed. Archived from the original on 10 February 2022. Retrieved 21 February 2021.
  7. 1 2 3 "Anusol HC- hydrocortisone acetate suppository". DailyMed. Archived from the original on 10 February 2022. Retrieved 21 February 2021.
  8. ↑ "Cortef- hydrocortisone tablet". DailyMed. Archived from the original on 17 April 2021. Retrieved 21 February 2021.
  9. 1 2 "Efmody EPAR". European Medicines Agency (EMA). 24 March 2021. Archived from the original on 14 June 2021. Retrieved 14 June 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  10. ↑ "Efmody Product information". Union Register of medicinal products. Archived from the original on 5 March 2023. Retrieved 3 March 2023.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Czock D, Keller F, Rasche FM, Häussler U (2005). "Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids". Clinical Pharmacokinetics. 44 (1): 61–98. doi:10.2165/00003088-200544010-00003. PMID   15634032. S2CID   24458998.
  12. 1 2 3 4 5 6 7 8 9 Lennernäs H, Skrtic S, Johannsson G (June 2008). "Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors". Expert Opinion on Drug Metabolism & Toxicology. 4 (6): 749–758. doi:10.1517/17425255.4.6.749. PMID   18611115. S2CID   73248541.
  13. 1 2 3 4 Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. (August 2013). "A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy". Allergy Asthma Clin Immunol. 9 (1): 30. doi: 10.1186/1710-1492-9-30 . PMC   3765115 . PMID   23947590.
  14. ↑ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. p. 762. ISBN   978-0-7817-1750-2. Archived from the original on 14 September 2016.
  15. ↑ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 202. ISBN   978-1-284-05756-0.
  16. ↑ "Hydrocortisone Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 20 September 2016. Retrieved 1 September 2016.
  17. ↑ U.S. patent 2,183,589
  18. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 484. ISBN   978-3-527-60749-5. Archived from the original on 10 January 2023. Retrieved 7 September 2020.
  19. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  20. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  21. ↑ "Hydrocortisone Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  22. ↑ Leite FM, Longui CA, Kochi C, Faria CD, Borghi M, Calliari LE, et al. (February 2008). "[Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency]". Arq Bras Endocrinol Metabol (in Portuguese). 52 (1): 101–8. doi: 10.1590/s0004-27302008000100014 . PMID   18345402.
  23. ↑ "Dexamethasone". drugs.com. Archived from the original on 21 June 2013. Retrieved 14 June 2013.
  24. ↑ Caldato MC, Fernandes VT, Kater CE (October 2004). "One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency". Arquivos Brasileiros de Endocrinologia e Metabologia. 48 (5): 705–712. doi: 10.1590/S0004-27302004000500017 . PMID   15761542. S2CID   13986916.
  25. ↑ Arvat E, Falorni A (2016). Cortisol Excess and Insufficiency. Frontiers of Hormone Research. S. Karger AG. p. 1-PA61. ISBN   978-3-318-05840-6. Archived from the original on 27 April 2023. Retrieved 10 April 2023.
  26. ↑ Ghizzoni L, Cappa M, Chrousos GP, Loche S, Maghnie M, eds. (2011). Pediatric Adrenal Diseases: Workshop, May 16-18, 2010, Turin (Italy). Karger Medical and Scientific Publishers. pp. 174–. ISBN   978-3-8055-9643-5. OCLC   1020003143. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
  27. 1 2 Wester RC, Maibach HI (1993). "Percutaneous absorption of topical corticosteroids". Current Problems in Dermatology. 21: 45–60. doi:10.1159/000422362. ISBN   978-3-8055-5712-2. PMID   8299376.
  28. ↑ Bormann JL, Maibach HI (September 2020). "Effects of anatomical location on in vivo percutaneous penetration in man". Cutaneous and Ocular Toxicology. 39 (3): 213–222. doi:10.1080/15569527.2020.1787434. PMID   32643443. S2CID   220439810.
  29. 1 2 3 Wester RC, Maibach HI (8 June 2021). "Regional Variation in Percutaneous Absorption". Percutaneous Absorption. CRC Press. pp. 165–174. doi:10.1201/9780429202971-11. ISBN   978-0-429-20297-1. S2CID   132864025.
  30. ↑ Britz MB, Maibach HI, Anjo DM (1980). "Human percutaneous penetration of hydrocortisone: the vulva". Archives of Dermatological Research. 267 (3): 313–316. doi:10.1007/BF00403852. PMID   7406539. S2CID   33367289.
  31. ↑ Oriba HA, Bucks DA, Maibach HI (February 1996). "Percutaneous absorption of hydrocortisone and testosterone on the vulva and forearm: effect of the menopause and site". The British Journal of Dermatology. 134 (2): 229–233. doi:10.1111/j.1365-2133.1996.tb07606.x. PMID   8746334. S2CID   30076779.
  32. ↑ Charmandari E, Johnston A, Brook CG, Hindmarsh PC (April 2001). "Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency". The Journal of Endocrinology. 169 (1): 65–70. doi: 10.1677/joe.0.1690065 . PMID   11250647.
  33. ↑ Boron WF, Boulpaep EL (2011). Medical Physiology (2nd ed.). Philadelphia: Saunders. ISBN   978-1-4377-1753-2.
  34. ↑ Nikolaou N, Hodson L, Tomlinson JW (March 2021). "The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies". The Journal of Steroid Biochemistry and Molecular Biology. 207: 105808. doi:10.1016/j.jsbmb.2021.105808. PMID   33418075. S2CID   230716310.
  35. 1 2 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 316. ISBN   978-1-4757-2085-3. Archived from the original on 8 September 2017.
  36. 1 2 Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 524–. ISBN   978-3-88763-075-1. Archived from the original on 10 January 2023. Retrieved 19 June 2020.
  37. 1 2 "Efmody: Pending EC decision". European Medicines Agency (EMA). 25 March 2021. Archived from the original on 4 May 2021. Retrieved 27 March 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  38. ↑ UKOpenGovernmentLicence.svg  This article incorporates text published under the British Open Government Licence : Competition and Markets Authority, Decision: Hydrocortisone tablets. Excessive and unfair pricing and Anti-competitive agreements , published 31 March 2022, accessed 1 June 2023
  39. ↑ Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. (October 2020). "Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis". JAMA. 324 (13): 1330–1341. doi: 10.1001/jama.2020.17023 . PMC   7489434 . PMID   32876694.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.